Evidence map›Paper›PMID 38384339›Full record

ArticleEClinicalMedicine2024

The RELIVE consortium for relapsed or refractory pediatric hepatoblastoma and hepatocellular carcinoma: a scoping review of the problem and a proposed solution.

Allison F O'Neill, Angela Trobaugh-Lotrario, James I Geller, Eiso Hiyama, Kenichiro Watanabe, Isabelle Aerts, Brice Fresneau, Fabienne Toutain, Michael J Sullivan, Howard M Katzenstein and 5 more

Open access · goldAbstract readScoping Review
PubMed Full text at PMC Publisher
In one paragraph

Article in EClinicalMedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Hepatoblastoma.Nature reviews. Disease primers · 2025
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 12 institutions in 6 countries.

Allison F O'NeillDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Angela Trobaugh-LotrarioProvidence Sacred Heart Children's Hospital, Spokane, WA, USA.
James I GellerDivision of Oncology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH, USA.
Eiso HiyamaDepartment of Pediatric Surgery, Hiroshima University Hospital, Hiroshima, Japan.
Kenichiro WatanabeShizuoka Children's Hospital, Shizuoka, Japan.
Isabelle AertsInstitut Curie, PSL Research University, Oncology Center SIREDO, Paris, France.
Brice FresneauDepartment of Children and Adolescent Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France.
Fabienne ToutainFaculty of Medicine, Department of Pediatrics, Gynecology and Obstetrics, University Hospital of Geneva-Department of Women, Child, and Adolescent, Onco-hematology Unit and Cansearch Research Platform for Pediatric Oncology and Hematology, University of Geneva, Geneva, Switzerland.
Michael J SullivanThe Royal Children's Hospital, Melbourne, Australia.
Howard M KatzensteinNemours Children's Hospital, Wilmington, DE, USA.
Bruce MorlandBirmingham Women's and Children's Hospital, Birmingham, UK.
Sophie BranchereauBicetre Hospital APHP, ParisSaclay University, France.
József ZsirosPrincess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Rudolf MaibachETOP IBCSG Partners Foundation, Bern, Switzerland.
Marc AnsariFaculty of Medicine, Department of Pediatrics, Gynecology and Obstetrics, University Hospital of Geneva-Department of Women, Child, and Adolescent, Onco-hematology Unit and Cansearch Research Platform for Pediatric Oncology and Hematology, University of Geneva, Geneva, Switzerland.
University of Geneva · CHAssistance Publique – Hôpitaux de Paris · FRCincinnati Children's Hospital Medical Center · USHarvard University · USHiroshima University Hospital · JPInternational Breast Cancer Study Group · CHPrincess Máxima Center · NLProvidence Sacred Heart Medical Center · USRoyal Children's Hospital · AUShizuoka Children's Hospital · JPUniversité Paris-Saclay · FRUniversité Paris Sciences et Lettres · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver tumors account for approximately 2% of all pediatric malignancies. Children with advanced stages of hepatoblastoma (HB) are cured only 50-70% of the time while children with advanced hepatocellular carcinoma (HCC) have a <20% 5-year overall survival. This scoping review was performed to highlight the paucity of rigorous, reliable data guiding the management of relapsed pediatric HB or HCC. When these patients are enrolled on prospective trials, the trials are often histology-agnostic, exclude patients less than a year of age, lack a liquid formulary of the drug under study, exclude recipients of a solid organ transplant, and enroll only 1-2 patients limiting the ability to deduce efficacious regimens for current use or future study. We highlight the creation of a global pediatric consortium intended to source retrospective relapse data from over 100 institutions spanning 4 continents. The data collected from this effort will inform future relapse trials.

Indexed as

CarcinomaHepatoblastomaPediatricRegistryRelapseReview

Identifiers

PMID38384339
PMCPMC10879668
OpenAlexW4391868308

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.